Findings
The review considered drugs that inhibit activated factor XI, known as FXIa, for secondary prevention after noncardioembolic ischemic stroke. The authors describe a treatment gap: recurrent strokes still occur with antiplatelet therapy, while conventional anticoagulation carries bleeding risks. FXIa inhibition is proposed as a way to suppress clot formation while preserving normal control of bleeding, but the available abstract does not provide clinical evidence establishing that proposed mechanism.
The authors report that phase 2 studies of asundexian and milvexian raised no major safety concern but did not show benefit on scan-based outcomes. They argue that clinically silent infarcts detected through imaging did not serve as a useful stand-in for symptomatic stroke outcomes in these studies.
In the phase 3 OCEANIC-STROKE study, participants received asundexian in addition to either one or two antiplatelet drugs. The review reports a 26% relative reduction in recurrent ischemic strokes, with results described as consistent among stroke subtypes. It also reports no increase in major bleeding or bleeding within the skull. The abstract gives no sample size, absolute event rates, confidence intervals or follow-up period, so the absolute benefit and statistical precision cannot be assessed.
Why it matters
If confirmed, the finding could point to an option for reducing repeat ischemic strokes without adding the bleeding burden associated with established anticoagulants. The evidence described here concerns people with previous noncardioembolic ischemic stroke; it cannot be generalized to every type of stroke or cardiovascular disease.
The broader evidence is mixed across clinical settings. Asundexian performed worse than apixaban in atrial fibrillation. Abelacimab, another treatment targeting FXIa, caused less bleeding than rivaroxaban in that setting, but its effect on clot-related events remains undetermined. These results do not establish that all FXIa inhibitors provide the same benefits.
What remains uncertain
Further trials must determine whether the reported stroke benefit is shared across this drug class, how long treatment should last and whether more complete FXIa inhibition changes benefits or harms. The abstract does not supply participant characteristics, full adverse-event totals or enough methodological information to judge potential bias. This is a journal record, but its peer-review status has not been verified from the supplied material.